SyntekaBio, Inc. (KOSDAQ:226330)

South Korea · Delayed Price · Currency is KRW

1,266.00

-40.00 (-3.06%)

At close: Oct 2, 2026

Market Cap	30.71B -51.5%
Revenue (ttm)	3.09B +132.3%
Net Income	-12.01B
EPS	-598.45
Shares Out	24.26M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	53,186
Open	1,327.00
Previous Close	1,306.00
Day's Range	1,258.00 - 1,327.00
52-Week Range	976.00 - 6,750.00
Beta	0.34
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About SyntekaBio

SyntekaBio, Inc. operates as an artificial intelligence new drug development company based on genomic big data primarily in South Korea. It derives new drug candidates using DeepMatcher, an AI drug development platform that combines new drug development technology and genomic big data technology. The company also researches and develops biomarker detection for individual cancer drug screening, disease susceptibility, immune typing, pharmacogenomic typing, and multi-omics information-based drug side effect prediction technology. The company was ... [Read more]

Industry Computer Programming, Data Processing, And Other Computer Related Services

Founded 2009

Employees 45

Stock Exchange KOSDAQ

Ticker Symbol 226330

Full Company Profile

Financial Performance

In 2025, SyntekaBio's revenue was 3.43 billion, an increase of 2736.72% compared to the previous year's 120.89 million. Losses were -17.38 billion, 140.9% more than in 2024.

Financial Statements